文献速递儿童呼吸儿童内分泌与遗传代谢

吸入性糖皮质激素与哮喘儿童骨折风险的相关性

Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma.
PubMed 文献 · JAMA Pediatr · 2018-01-01

这项基于人群的巢式病例对照研究纳入19 420名2-18岁哮喘儿童,发现当前、近期或过去使用吸入性糖皮质激素与首次骨折风险无显著关联,而全身性糖皮质激素使用与骨折 odds 增加显著相关。

要点

  • 吸入性糖皮质激素当前使用与骨折风险无显著关联(OR 1.07,95%CI 0.97-1.17)。
  • 全身性糖皮质激素使用与骨折 odds 增加显著相关(OR 1.17,95%CI 1.04-1.33)。

核心结论

  • 在儿童哮喘人群中,全身性糖皮质激素而非吸入性糖皮质激素与骨折 odds 增加显著相关。

研究设计与样本

  • 基于人群的巢式病例对照研究,使用加拿大安大略省卫生行政数据库识别2003年4月1日至2014年3月31日期间诊断为哮喘的2-18岁儿童,共纳入19 420名儿童。

主要发现

  • 与无吸入性糖皮质激素使用相比,当前使用(OR 1.07;95%CI 0.97-1.17)、近期使用(OR 0.96;95%CI 0.86-1.07)或过去使用(OR 1.00;95%CI 0.91-1.11)与哮喘诊断后首次骨折无显著关联。
  • 在1年回顾期内使用全身性糖皮质激素与骨折 odds 增加显著相关(OR 1.17;95%CI 1.04-1.33)。

关键数值与推荐

  • 当前使用者定义为索引日期前90天内配药,近期使用者为91-180天,过去使用者为181-365天。
  • 骨折结局通过国际疾病分类第10版编码识别首次急诊就诊。

临床怎么用

  • 对于哮喘儿童,吸入性糖皮质激素使用未显示与骨折风险显著增加相关,临床可参考此结果评估用药顾虑。
  • 使用全身性糖皮质激素的哮喘儿童骨折 odds 较高,临床应关注其骨骼健康风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Daily use of inhaled corticosteroids is a widely recommended treatment for mild persistent asthma in children. There is concern that, similar to systemic corticosteroids, inhaled corticosteroids may have adverse effects on bone health. OBJECTIVE: To determine whether there is an increased risk of bone fracture associated with inhaled corticosteroid use in children with asthma. DESIGN, SETTING, AND PARTICIPANTS: In this population-based nested case-control study, we used health administrative databases to identify a cohort of children aged 2 to 18 years with a physician diagnosis of asthma between April 1, 2003, and March 31, 2014, who were eligible for public drug coverage through the Ontario Drug Benefit Program (Ontario, Canada). We matched cases of first fracture after asthma diagnosis to fracture-free controls (ratio of 1 to 4) based on date of birth (within 1 year), sex, and age at asthma diagnosis (within 2 years). We used a 1-year lookback period to ascertain history of inhaled corticosteroid use. Multivariable conditional logistic regression was used to obtain an odds ratio (OR) with 95% confidence interval for fracture, comparing no inhaled corticosteroid use vs current, recent, and past use. EXPOSURES: Inhaled corticosteroid use during the child's 1-year lookback period, measured as current user if the prescription was filled less than 90 days prior to the index date, recent user (91-180 days), past user (181-365 days), or no use. MAIN OUTCOMES AND MEASURES: First emergency department visit for fracture after asthma diagnosis, identified using International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes. RESULTS: This study included 19 420 children (61.0% male; largest proportion of children, 31.5%, were aged 6-9 years at their index date). The multivariable regression results did not show a significant association between first fracture after asthma diagnosis and current use (OR, 1.07; 95% CI, 0.97-1.17), recent use (OR, 0.96; 95% CI, 0.86-1.07), or past use (OR, 1.00; 95% CI, 0.91-1.11) of inhaled corticosteroids, compared with no use, while adjusting for sociodemographic factors and other medication use. However, use of systemic corticosteroids in the 1-year lookback period resulted in greater odds of fracture (OR, 1.17; 95% CI, 1.04-1.33). CONCLUSIONS AND RELEVANCE: Systemic corticosteroids, but not inhaled corticosteroids, were significantly associated with increased odds of fracture in the pediatric asthma population.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Gray N, Howard A, Zhu J, et al. Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma. JAMA Pediatr. 2018. PMID: 29131874. doi:10.1001/jamapediatrics.2017.3579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。